MedDataX Logo

Impact of Peripheral Afferent Input on Central Neuropathic Pain

NCT ID: NCT05646810

Last Updated: 2022-12-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-12-01

Study Completion Date

2023-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The overarching aim of this study is to investigate the contribution of peripheral afferent input to spontaneous and evoked central neuropathic pain after a spinal cord lesion or disease.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A key question that has been subject to longstanding debates in the field relates to the sites and mechanisms within the peripheral or central nervous system that potentially perpetuate chronic spontaneous and evoked central neuropathic pain. The investigators hypothesize that spontaneous central neuropathic pain depends on continuous, "physiological" somatosensory input from the painful body region in the periphery. Thus, spontaneous central neuropathic pain results from pathological gain control in central somatosensory networks with decreased activation thresholds for thermo- and mechanosensitive peripheral afferents.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Spinal Cord Injuries Spinal Cord Diseases Syringomyelia

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

central pain peripheral afferent input neuropathic pain spinal cord injury

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Lidocaine

Nerve block

Group Type ACTIVE_COMPARATOR

Lidocaine (10 mg/ml)

Intervention Type DIAGNOSTIC_TEST

Lidocaine (10 mg/ml) will be injected according to established protocols using ultrasound guidance and an aseptic technique by an experienced anesthesiologist.

Isotonic saline

Nerve block

Group Type PLACEBO_COMPARATOR

Isotonic saline

Intervention Type DIAGNOSTIC_TEST

Isotonic saline will be injected according to established protocols using ultrasound guidance and an aseptic technique by an experienced anesthesiologist.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lidocaine (10 mg/ml)

Lidocaine (10 mg/ml) will be injected according to established protocols using ultrasound guidance and an aseptic technique by an experienced anesthesiologist.

Intervention Type DIAGNOSTIC_TEST

Isotonic saline

Isotonic saline will be injected according to established protocols using ultrasound guidance and an aseptic technique by an experienced anesthesiologist.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Definite central neuropathic pain according to current diagnostic algorithms involving at least both feet or both hands bilaterally and symmetrically with regard to the expected neuroanatomical distribution of the nerve block.
* Patients with spinal cord injury. For patients with pain in both legs, the injury has to be incomplete. For patients with pain in both arms, the injury can be complete or incomplete. The pain in the area that will be investigated (region of interest) has to be in an area with at least some preservation of sensation
* An intensity of spontaneous pain of ≥4 NRS \[0-10\] in the region of interest during the screening visit and at the day of the intervention.
* Participant is able and willing to give informed consent.
* For female subjects of childbearing potential: A negative pregnancy test and either use of highly effective contraception or sexual abstinence

Exclusion Criteria

* Conus/cauda involvement or evidence of peripheral neuropathic pain due to documented peripheral lesion.
* Other known neurological and psychiatric conditions
* History or symptoms of significant diseases that may confound the measurements or represent contra-indications for the intervention (e.g., neuropathy following cancer or metabolic diseases such as diabetes mellitus, liver diseases, and kidney diseases.
* Cardiovascular diseases that preclude the anaesthetic intervention (e.g., arrythmias).
* Concomitant nociceptive pain within the innervation territory of the planned nerve block.
* Unable to understand and speak Danish
* Changes in pain medication within the last 4 weeks prior to the intervention.
* Treatment with warfarin or other blood thinning medications, that contraindicates regional anesthesia if the treating physician cannot recommend that such treatments are paused for at least 7 days before the study day
* Infection or skin disease in planned injection area
* Allergy for local anesthetics
* Pregnancy or lactation.
* Alcohol or drug abuse
* Pain intensity below 4 in the region of interest at the baseline measurement before the nerve block
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Aarhus

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jan Rosner, MD

Role: PRINCIPAL_INVESTIGATOR

Danish Pain Research Center, Department of Clinical Medicine, Aarhus University

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Nanna B. Finnerup, Professor

Role: CONTACT

Phone: 0045 784 63380

Email: [email protected]

Jan Rosner, MD

Role: CONTACT

Phone: 0041 79 952 4551

Email: [email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

39451

Identifier Type: -

Identifier Source: org_study_id